SMMT logo

SMMT Summit Therapeutics Inc

$16.76
$0.065
(0.39%)
Today
Closed $16.76
$0.0611
(0.36%)
After Hours
83

Extremely Bullish Sentiment

How do you feel about SMMT?

Loading...
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.
Stocktwits
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.read more...
Benzinga
Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’
The firms will begin their collaboration with a Phase 3 study of Ivonescimab in combination with Datroway in first-line triple-negative breast cancer
Stocktwits
Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab
(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZenca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple solid tumors, including lung and brea...
Nasdaq News: Markets
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with...
Business Wire
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.
Zacks
High-Stakes October Puts These Biotechs in the Spotlight
The biotechnology sector is entering a catalyst-heavy stretch, with Iovance Biotherapeutics (NASDAQ:IOVA), NeOnc Technologies Holdings (NASDAQ:NTHI), and Summit Therapeutics (NASDAQ:SMMT) approaching potentially significant commercial, clinical, and regulatory milestones.
24-7 Market News
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
AstraZeneca buys $2 billion in Summit Therapeutics equity to test ivonescimab with ADCs, providing capital.read more...
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%read more...
Benzinga